Two Sigma Investments LP bought a new position in shares of LifeVantage Corp (NASDAQ:LFVN) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 15,276 shares of the company’s stock, valued at approximately $157,000. Two Sigma Investments LP owned 0.11% of LifeVantage at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently made changes to their positions in LFVN. Renaissance Technologies LLC raised its holdings in shares of LifeVantage by 2.8% in the 4th quarter. Renaissance Technologies LLC now owns 1,148,905 shares of the company’s stock valued at $17,934,000 after buying an additional 31,470 shares during the period. Acadian Asset Management LLC boosted its holdings in LifeVantage by 0.6% during the 1st quarter. Acadian Asset Management LLC now owns 545,187 shares of the company’s stock valued at $5,615,000 after acquiring an additional 3,014 shares during the period. State Street Corp grew its position in LifeVantage by 3.0% in the 1st quarter. State Street Corp now owns 257,282 shares of the company’s stock valued at $2,650,000 after acquiring an additional 7,380 shares in the last quarter. Geode Capital Management LLC increased its stake in LifeVantage by 13.1% during the fourth quarter. Geode Capital Management LLC now owns 213,793 shares of the company’s stock worth $3,336,000 after purchasing an additional 24,811 shares during the period. Finally, Jacobs Levy Equity Management Inc. lifted its position in shares of LifeVantage by 14.0% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 163,855 shares of the company’s stock worth $2,558,000 after purchasing an additional 20,076 shares in the last quarter. Institutional investors and hedge funds own 47.70% of the company’s stock.
In other LifeVantage news, CEO Darren Jay Jensen sold 4,500 shares of the stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $14.41, for a total value of $64,845.00. Following the transaction, the chief executive officer now directly owns 480,585 shares in the company, valued at $6,925,229.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Justin Rose sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $12.00, for a total transaction of $30,000.00. Following the sale, the insider now directly owns 136,809 shares in the company, valued at approximately $1,641,708. The disclosure for this sale can be found here. Over the last three months, insiders sold 12,750 shares of company stock worth $164,215. Insiders own 6.80% of the company’s stock.
LifeVantage (NASDAQ:LFVN) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $0.13 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.16 by ($0.03). LifeVantage had a net margin of 5.06% and a return on equity of 43.08%. The company had revenue of $56.08 million during the quarter. Equities analysts anticipate that LifeVantage Corp will post 0.77 earnings per share for the current fiscal year.
Separately, ValuEngine raised shares of LifeVantage from a “hold” rating to a “buy” rating in a research note on Tuesday, March 17th.
LifeVantage Corporation engages in the identification, research, development, and distribution of nutraceutical dietary supplements and skin care products. The company offers Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skin care product; Axio, a line of energy drink mixes; Omega+, a fish oil dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and Vitamin D3; and PhysIQ, a weight management system, as well as Petandim for Dogs, a companion pet supplement formulated to treat oxidative stress in dogs.
Receive News & Ratings for LifeVantage Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeVantage and related companies with MarketBeat.com's FREE daily email newsletter.